A company based in Northern Ireland is advancing a rapid blood test to screen for a heart attack, allowing for doctors to more quickly treat affected patients. Randox Health's low-cost diagnostic has shown promise in early testing.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline's cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.
Philips Healthcare is touting some positive early results from a field study of its new hand-held blood test to spot patients at high risk for heart attacks or other "acute cardiac events."
In a study published in the journal Nature Materials, University of Pennsylvania scientists describe a hydrogel they developed that is designed to be applied directly to heart muscle to reduce continuing damage after a heart attack.
Researchers believe they've come up with a new biomarker blood test that can diagnose heart attack much more quickly than existing tests allow and thereby reduce the potential for long-term harm.
An experimental gene therapy developed by investigators at the Icahn School of Medicine at Mount Sinai successfully regenerated heart muscle in pigs following a heart attack.
High-density lipoproteins are a key component in the transportation of molecules such as cholesterol and fats inside the body. And by using a synthetic nanoparticle version of these natural vehicles, researchers have found a way to deliver drugs to the heart that could potentially prevent repeat heart attacks or stroke.
A microparticle therapy developed by researchers at Northwestern Medicine and the University of Sydney in Australia may be able to restore heart tissue damaged by inflammation following a heart attack.
GlaxoSmithKline has racked up a slate of drug approvals this year, an impressive accomplishment for a company that had to endure a lengthy fallow period in R&D after it reorganized its extensive research operations.